A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
BeOne Medicines
BeOne Medicines
AstraZeneca
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Bayer
Roswell Park Cancer Institute
Zymeworks BC Inc.
National Cancer Institute (NCI)
Nammi Therapeutics Inc
OncoC4, Inc.
Compass Therapeutics
National Institutes of Health Clinical Center (CC)
Alnylam Pharmaceuticals
University of Hawaii
Sotio Biotech Inc.
Aptamer Sciences, Inc.
Virginia Commonwealth University
Guangzhou FineImmune Biotechnology Co., LTD.
National Cancer Institute (NCI)